Effect of bosentan therapy on ventricular and atrial function in adults with Eisenmenger syndrome. A prospective, multicenter study using conventional and Speckle tracking echocardiography
- 296 Downloads
The effect of bosentan on the ventricular and atrial performance in patients with Eisenmenger syndrome is unclear. In adult patients with Eisenmenger syndrome, we aimed to evaluate the midterm effect of bosentan on physical exercise, ventricular and atrial function, and pulmonary hemodynamics.
Forty adult patients before and after 24 weeks bosentan therapy underwent 6 min walk test, two-dimensional speckle tracking echocardiography, plasma NT-proBNP measurement and cardiac catheterization.
After 24 weeks, bosentan therapy an improvement was observed regarding the 6 min walk distance from a median (quartile 1–quartile 3) of 382.5 (312–430) to 450 (390–510) m (p = 0.0001), NT-proBNP from 527.5 (201–1,691.25) to 369 (179–1,246) pg/ml (p = 0.021), right ventricular mean longitudinal systolic strain from 18 (13–22) to 19 (14.5–25) % (p = 0.004), left ventricular mean longitudinal systolic strain from 16 (12–21) to 17 (16–22) % (p = 0.001), right atrial mean peak longitudinal strain from 26 (18–34) to 28 (22–34) % (p = 0.01) and right atrial mean peak contraction strain from 11 (8–16) to 13 (11–16) % (p = 0.005). The invasively obtained Qp:Qs and Rp:Rs did not significantly change under bosentan therapy.
In adult patients with Eisenmenger syndrome, bosentan therapy improves ventricular and atrial functions resulting in enhancement of physical exercise and reduction in the NT-proBNP level, while the pulmonary vascular resistance does not change substantially.
KeywordsPulmonary arterial hypertension, echocardiography Myocardial contraction Remodeling
- 2-D STE
Two-dimensional speckle tracking echocardiography
Six-minute walk test
Congenital heart defect
N-terminal pro-B-type natriuretic peptide
Peak atrial contraction strain
Pulmonary arterial hypertension
Peak atrial longitudinal strain
Pulmonary blood flow:systemic blood flow
Region of interest
Pulmonary resistance:systemic resistance
Tricuspid annular plane systolic excursion
The authors would like to acknowledge the collaboration and commitment of all the local investigators and their staff. Participating centers (listed in alphabetical order), in which patients have been included: Heart and Diabetes Center NRW, Bad Oeynhausen: D. Kececioglu, P. Beerbaum, S. Sarikouch, R. Schäffler. Deutsches Herzzentrum Berlin, Berlin: P. Ewert. Justus-Liebig University Giessen, Giessen: D. Schranz, R. Zimmermann. Saarland University Hospital, Homburg/Saar: A. Lindinger, J. Olchavary. Deutsches Herzzentrum Muenchen, Technische Universitaet Muenchen, Munich: J. Hess, H. Kaemmerer Consultant team in echocardiography: M. Vogel (Munich), M. Vogt (Munich). We are further indebted to Professor M. Böhm (Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital) for his careful review of and valuable comments on the manuscript. Ms. Verena Materna, Koordinierungszentrum fuer Klinische Studien, Charité, Berlin for the organizing support. Ms. Brigitte Tüllmann, Koordinierungszentrum fuer Klinische Studien, Charité, Berlin for the monitoring work. Anne M. Gale, ELS, of Deutsches Herzzentrum Berlin, for editorial assistance. Ulrike Bauer, MD and Thomas Pickardt, Ph.D., Competence Network for Congenital Heart Defects, for the central research management. This work was supported by the Competence Network for Congenital Heart Defects funded by the Federal Ministry of Education and Research (BMBF), FKZ 01G10210, and by an unrestricted grant by Actelion Pharmaceuticals Deutschland GmbH.
Conflict of interest
The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.
- 6.ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117Google Scholar
- 7.Koestenberger M, Nagel B, Ravekes W et al (2011) Tricuspid annular plane systolic excursion and right ventricular ejection fraction in pediatric and adolescent patients with tetralogy of Fallot, patients with atrial septal defect, and age-matched normal subjects. Clin Res Cardiol 100:67–75PubMedGoogle Scholar
- 9.Geyer H, Caracciolo G, Abe H, et al (2010) Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr 23:351–69; quiz 453–5Google Scholar
- 23.Iwanaga Y, Kihara Y, Hasegawa K et al (1998) Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 98:2065–2073PubMedCrossRefGoogle Scholar
- 25.Fraccarollo D, Hu K, Galuppo P, et al (1997) Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96(11):3963–73Google Scholar
- 30.Magga J, Vuolteenaho O, Marttila M et al (1997) Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 96:3053–3062PubMedCrossRefGoogle Scholar